International Journal of Gynecological Cancer最新文献

{"title":"Duplication of inferior vena cava: a case of retroperitoneal secondary cytoreductive surgery.","authors":"Giulio Bonaldo, Vicente Bebia","doi":"10.1136/ijgc-2024-005902","DOIUrl":"10.1136/ijgc-2024-005902","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101890"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer.","authors":"Gottfried E Konecny, Tara M Davidson, Coriolan L Lebreton, Leah A Marsh, Deandra K Chetram, Hunter J Atkinson, Melissa C Larson, Ann L Oberg, Nabilah Abdelaal, Jordyn Silverstein, Aminah Jatoi, Anita Washburn, Jill Burton, Sean Dowdy, Liying Zhang, Dorothy Hallberg, Victor E Velculescu, Dennis J Slamon, Andrea E Wahner-Hendrickson","doi":"10.1016/j.ijgc.2025.102028","DOIUrl":"10.1016/j.ijgc.2025.102028","url":null,"abstract":"<p><strong>Objective: </strong>We describe a phase II clinical trial evaluating the safety and efficacy of the oral CDK4/6 inhibitor palbociclib in patients with recurrent ovarian cancer.</p><p><strong>Methods: </strong>Eligible patients with Response Evaluation Criteria in Solid Tumors (RECIST) and/or CA-125 measurable recurrent ovarian cancer were treated with oral palbociclib 125 mg daily for 21 days of a 28-day cycle. Patients with hormone receptor-positive tumors were allowed to concurrently receive an aromatase inhibitor. The primary endpoint was the biochemical response rate, determined by CA-125 response based on Gynecologic Cancer InterGroup criteria. Genomic analyses were performed using targeted next-generation sequencing.</p><p><strong>Results: </strong>The biochemical response rate among 40 patients was 8.3% (95% CI 2.2 to 23.6), and the objective response rate by CA-125 criteria and/or RECIST was 10.5% (95% CI 3.4 to 25.7). Median progression-free survival was 3.2 months. Progression-free survival rates at 6 and 12 months were 25% and 7.5%, respectively. Two patients diagnosed with recurrent low-grade serous ovarian cancer experienced long-term disease stabilization for more than 37 and 9 months, triggering a review of 12 additional low-grade serous ovarian cancer patients treated outside of the phase II trial. Exploratory tumor genomic profiling revealed potential predictors of sensitivity (CDKN2A deletion) or resistance (CCNE1 amplification or RB1 deletion), which require additional independent validation.</p><p><strong>Conclusions: </strong>Palbociclib demonstrated only modest clinical activity in unselected patients with ovarian cancer. However, cyclin-dependent kinases 4/6 inhibition showed promising clinical activity in low-grade serous ovarian cancer, warranting further study in this subtype. Further biomarker analyses may facilitate patient selection in high-grade serous ovarian cancer.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102028"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.","authors":"Alexandra H Smick, Lindsay Brennan, Jordyn Silverstein, Ritu Salani, Gottfried Konecny, Dana M Chase","doi":"10.1016/j.ijgc.2025.102016","DOIUrl":"10.1016/j.ijgc.2025.102016","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate prescribing patterns, toxicities, and outcomes among patients receiving mirvetuximab for platinum-resistant ovarian cancer.</p><p><strong>Methods: </strong>This retrospective study included patients with platinum-resistant ovarian cancer with high folate receptor alpha expression treated with mirvetuximab at a single institution (2018-2023). Patients were categorized based on treatment immediately preceding mirvetuximab: the taxane group received taxane treatment; the non-taxane group received other therapy. An age-matched cohort of platinum-resistant patients not treated with mirvetuximab was included for survival comparison. Statistical analyses included descriptive statistics, Kaplan-Meier curves, log-rank tests, Wilcoxon rank-sum tests, and Cox models.</p><p><strong>Results: </strong>Forty-one patients received mirvetuximab, with a median of 8 cycles (range; 1-47). Grade ≥3 adverse events included ocular (n = 6; 15%), hematologic (n = 1; 2%), neuropathy (n = 1; 2%), and pneumonitis (n = 1; 2%). Dose reductions and delays occurred in 26 (63%) and 21 (51%) patients, respectively. Mirvetuximab was discontinued in 40 patients (98%), most commonly due to disease progression (n = 35; 88%). Mirvetuximab-treated patients had longer median overall survival from diagnosis compared to the age-matched cohort without mirvetuximab exposure (83.12 vs 52.14 months; HR 0.34, 95% CI 0.18 to 0.64, p < .001). Among patients who received taxane therapy immediately before mirvetuximab (n = 9), average treatment duration was 5 months (9 cycles), with no grade ≥3 neuropathy. In those who received a non-taxane regimen immediately before mirvetuximab (n = 32), average treatment duration was 6 months (8 cycles), with 1 patient (3%) experiencing grade ≥3 neuropathy. Median progression-free survival was similar between groups (5.49 vs 6.28 months; HR 1.30, 95% CI 0.61 to 2.78, p = .50), but overall survival was shorter in the taxane group (11.28 vs 21.02 months; HR 2.47, 95% CI 1.01 to 6.04, p = .048).</p><p><strong>Conclusions: </strong>Real-world experience with mirvetuximab demonstrated a favorable safety profile and clinical benefit in platinum-resistant ovarian cancer. Taxane therapy immediately preceding mirvetuximab was associated with shorter overall survival but not increased neurotoxicity.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102016"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on \"the effect of prior adjuvant radiotherapy on immunotherapy outcomes in recurrent endometrial cancer\" by Guo et al.","authors":"Gabriel Levin, Shuk On Annie Leung","doi":"10.1016/j.ijgc.2025.101963","DOIUrl":"10.1016/j.ijgc.2025.101963","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101963"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Checkpoint inhibitors in ovarian cancer maintenance: a promise not fulfilled.","authors":"Renata Arakelian, Luiza Andrade Mussi, Mariana Carvalho Gouveia, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.102037","DOIUrl":"10.1016/j.ijgc.2025.102037","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102037"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10-step technique for hepatic mobilization: essential anatomy and surgical approach.","authors":"Tiermes Marina, Víctor Lago, Pablo Padilla-Iserte, Berta Díaz-Feijoo, Santiago Domingo","doi":"10.1016/j.ijgc.2025.102031","DOIUrl":"10.1016/j.ijgc.2025.102031","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 10","pages":"102031"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on \"Silicon dioxide, sodium selenite and citric acid vaginal gel, HPV infection, and cervical preinvasive disease: a narrative review\" by Emmanuel Sánchez Díaz.","authors":"Rene Pareja, Emmanuel Sánchez Díaz, Gabriel Levin","doi":"10.1016/j.ijgc.2025.102669","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102669","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102669"},"PeriodicalIF":4.7,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response to: \"Methodological concerns regarding AGO score validation in low-grade ovarian cancers\".","authors":"Emel Canaz, Eser S Ozyurek, Jalid Sehouli","doi":"10.1016/j.ijgc.2025.102658","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102658","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102658"},"PeriodicalIF":4.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of artificial intelligence applied to ultrasound in endometrial cancer: a systematic review.","authors":"Marianna Ciancia, Francesca Moro, Martina Bertoni, Giulia Baldassari, Pierpaolo Schips, Francesco Fanfani, Anna Fagotti, Antonia Carla Testa","doi":"10.1016/j.ijgc.2025.102653","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102653","url":null,"abstract":"<p><strong>Objective: </strong>To synthesize the application of artificial intelligence (AI) in ultrasound imaging for the assessment of endometrial cancer, with a focus on methodological approaches and diagnostic accuracy in predicting different outcomes.</p><p><strong>Methods: </strong>PubMed, Scopus, and Web of Science databases were searched from inception up to January 16, 2025. Studies applying AI to ultrasound imaging in the diagnosis, staging, and management of endometrial malignant pathology were included. Quality assessment of the retrieved studies was performed using the Quality Assessment Tool for Artificial Intelligence-Centered Diagnostic Test Accuracy Studies (QUADAS-AI). The protocol was registered in the PROSPERO database (registration record CRD42025648961).</p><p><strong>Results: </strong>Thirty studies were included: 18 (60%) distinguished between benign and malignant endometrial lesions, 4 (13.3%) focused on predicting lymph node metastases, 3 (10%) evaluated myometrial invasion, and 2 (6.6%) classified tumor risk. Additionally, 2 studies assessed disease-free survival (6.6%), while another developed a model for the automated identification of endometrial lesions (3.3%). According to QUADAS-AI, most studies were at high risk of bias for subject selection (eg, sample size not specified, imaging preprocessing not performed) (27/30, 90%) and the index test (no external validation) (27/30, 90%) domains, and at low risk of bias for the reference standard (target condition correctly classified by the reference standard) (29/30, 97%) and the workflow (reasonable time between index test and reference standard) (29/30, 97%) domains. Models were externally validated in 3/30 studies (10%), internally cross-validated in 3/30 (10%), internally hold-out validated in 13/30 (43.3%), and not validated in 11/30 (36.7%).</p><p><strong>Conclusions: </strong>Published research on AI applications in ultrasound for endometrial cancer primarily focuses on developing classification models to distinguish benign from malignant endometrial lesions and to stage the disease. Overall, ultrasound-based AI models have demonstrated strong predictive performance. However, most studies are limited by small sample sizes and a lack of external validation.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102653"},"PeriodicalIF":4.7,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of \"aggressive\" histology in surgically staged clinically uterine-confined endometrial carcinoma.","authors":"Christian Dagher, Jennifer J Mueller, Yukio Sonoda, Amir Momeni-Boroujeni, Vicky Makker, Roisin E O'Cearbhaill, Kaled Alektiar, Nadeeem R Abu-Rustum, Mario M Leitao","doi":"10.1016/j.ijgc.2025.102656","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102656","url":null,"abstract":"<p><strong>Objective: </strong>We compared oncologic outcomes across \"aggressive\" histopathological subtypes of apparent early-stage, high-grade endometrial carcinoma.</p><p><strong>Methods: </strong>Patients who underwent surgical staging at our institution for newly diagnosed high-grade endometrial adenocarcinoma between January 1, 2009, and June 30, 2021, were retrospectively identified. We defined \"aggressive\" histology as International Federation of Obstetrics and Gynecology grade 3 endometrioid, serous, clear cell, carcinosarcoma, mixed, and undifferentiated/dedifferentiated subtypes. Clinicopathologic details were extracted from medical records. Continuous variables were analyzed using the Kruskal-Wallis test, categorical variables using Fisher's exact test or the χ² test, and survival outcomes using the Kaplan-Meier method and Cox proportional hazards models.</p><p><strong>Results: </strong>Of 1087 patients, 308 (28.3%) had grade 3 endometrioid adenocarcinoma, 357 (32.8%) serous adenocarcinoma, 64 (5.9%) clear cell carcinoma, 194 (17.8%) carcinosarcoma, 101 (9.3%) mixed adenocarcinoma, and 63 (5.8%) undifferentiated/dedifferentiated adenocarcinoma. Overall, 719 patients (66.1%) had International Federation of Obstetrics and Gynecology 2009 stage I, 51 (4.7%) stage II, 232 (21.3%) stage III, and 85 (7.8%) stage IV disease. Median age at surgery was 65.1 years (range; 24.8-92.1) and varied among histologies (p < .001). Overall, 462 patients (42.5%) had lymphovascular invasion, 333 (30.6%) had deep myometrial invasion (≥50%), and 160 (15.0%) had positive peritoneal cytology; all varied across histologies (p < .001). Rates of 5-year progression-free and overall survivals were 79% (standard error [SE] ± 3%) and 83% (SE ± 2%) for grade 3 endometrioid, 63% (SE ± 3%) and 66% (SE ± 3%) for serous, 73% (SE ± 6%) and 77% (SE ± 6%) for clear cell, 51% (SE ± 4%) and 54% (SE ± 4%) for carcinosarcoma, 59% (SE ± 5%) and 65% (SE ± 5%) for mixed, and 71% (SE ± 6%) and 76% (SE ± 6%) for undifferentiated/dedifferentiated (P<.001 for both). Peritoneal cytology, lymphovascular invasion, and age at surgery were independent predictors of worse progression-free and overall survivals on multivariable analysis.</p><p><strong>Conclusions: </strong>High-grade \"aggressive\" histologies in endometrial cancer are diverse tumors with distinct oncologic outcomes; therefore, they should not be treated as a single entity or used as a staging criterion.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 11","pages":"102656"},"PeriodicalIF":4.7,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}